Urology
Volume 75, Issue 3 , Pages 526-532.e18 , March 2010

Economic Costs of Overactive Bladder in the United States

  • Michael L. Ganz

      Affiliations

    • Abt Bio-Pharma Solutions, Inc., Lexington, Massachusetts
    • Corresponding Author InformationReprint requests: Michael L. Ganz, M.S., Ph.D., Abt Bio-Pharma Solutions, Inc, 181 Spring St, Lexington, MA 02421
    • ,
  • Amy M. Smalarz

      Affiliations

    • Abt Bio-Pharma Solutions, Inc., Lexington, Massachusetts
    • ,
  • Tracey L. Krupski

      Affiliations

    • Department of Urology, University of Virginia, Charlottesville, Virginia
    • ,
  • Jennifer T. Anger

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, California
    • ,
  • Jim C. Hu

      Affiliations

    • Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Kim U. Wittrup-Jensen

      Affiliations

    • Bayer Schering Pharma, Berlin, Germany
    • ,
  • Chris L. Pashos

      Affiliations

    • Abt Bio-Pharma Solutions, Inc., Lexington, Massachusetts

Received 5 May 2009 ,Accepted 26 June 2009.

References 

  1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49
  2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–336
  3. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63:461–465
  4. Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. BJU Int. 2005;96(Suppl 1):43–45
  5. Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol. 2006;175:S5–S10
  6. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Health Care Financ Rev. 1985;7:61–80
  7. U.S. Census Bureau. The 2008 Statistical Abstract of the United States. Washington, DC: U. S. Census Bureau.
  8. National Center for Health Statistics. Ambulatory Health Care Data. http://www.cdc.gov/nchs/about/ahcd/ahcd1.htmAccessed February 25, 2008
  9. Ingenix, Inc. National Fee Analyzer. Salt Lake City, UT: Ingenix Inc; 2004;
  10. Centers for Medicare and Medicaid Services. Medicare physician Fee schedule look-up. http://www.cms.hhs.gov/physicians/mpfsapp/default.aspAccessed February 25, 2008
  11. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy. 2006;26:1694–1702
  12. Nygaard IE, Thom DH, Calhoun EA. Urinary incontinence in women. In:  Litwin MS,  Saigal CS editor. Urologic Diseases in America, NIH Publication No. 07-5512. Washington, DC: Government Printing Office; 2007;p. 157–193
  13. Ouslander JG, Shih YT, Malone-Lee J, et al. Overactive bladder: special considerations in the geriatric population. Am J Manag Care. 2000;6:S599–S606
  14. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–1395
  15. Wu EQ, Birnbaum H, Marynchenko M, et al. Employees with overactive bladder: work loss burden. J Occup Environ Med. 2005;47:439–446
  16. Subak LL, Brown JS, Kraus SR, et al. The “costs” of urinary incontinence for women. Obstet Gynecol. 2006;107:908–916
  17. Congressional Budget Office. The Longterm Outlook for Health Care Spending. Washington, DC: Congressional Budget Office; 2007;
  18. Congressional Budget Office. February 15 2008 Update to the CBO's Economic Projections for Calendar Years 2008-18. Washington, DC: Congressional Budget Office; 2008;
  19. Klotz T, Bruggenjurgen B, Burkart M, et al. The economic costs of overactive bladder in Germany. Eur Urol. 2007;51:1654–1663
  20. Reeves P, Irwin D, Kelleher C, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol. 2006;50:1050–1057

PII: S0090-4295(09)02311-5

doi: 10.1016/j.urology.2009.06.096

Urology
Volume 75, Issue 3 , Pages 526-532.e18 , March 2010

Article Tools

* Image Usage & Resolution